It could be an industry giant in the making.Companies with exciting prospects aren't always of the popular, headline-grabbing variety. Some little-known stocks are worth serious consideration, too.Take Axsome Therapeutics (AXSM), a mid-cap biotech company not involved in the rapidly growing area of GLP-1 weight loss drugs. Though it's doing so quietly, this drugmaker has performed more or less in line with the broader market this year, and there are good reasons to believe it could produce strong returns ov ...

Axsome Therapeutics, Inc. (AXSM) announced that the FDA has accepted its resubmitted new drug application (NDA) seeking approval for AXS-07 for the acute treatment of migraine.A final decision from the regulatory body is expected on Jan. 31, 2025. The FDA has designated the NDA resubmission as a Class 2 resubmission.Shares of AXSM were up 6.6% on Sept. 4 following the announcement of the news.Year to date, shares of Axsome have rallied 20.1% against the industry’s decrease of 0.9%.Image Source: Zacks Invest ...

A month has gone by since the last earnings report for Axsome Therapeutics (AXSM) . Shares have added about 4.8% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Axsome due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Axsome Q2 Loss Widens Y/Y, Revenues Beat Estimat ...

Axsome Therapeutics’ (AXSM) first marketed drug, Auvelity (AXS-05), was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.The drug generated sales worth $118.4 million in the first half of 2024, up 172.8% year over year, owing to strong underlying demand. The momentum is likely to continue for the remainder of 2024.Axsome is also conducting several label expansion studies on Auvelity targeting other centra ...

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was filed against Axsome on May 13, 2022 with a Class Period from December 30, 2019 to April 22, 2022. Our investigation concerns whether the board of directors of Axsome have breached their fiduciary duties to the company. Axs ...

J Studios Introduction My last look at Axsome Therapeutics, Inc. (NASDAQ:AXSM) followed their Q4 2023 eamings report, in which Auvelity (destromethorphan-bupropion), the nsy substan and and ancel and the colorios in revented in the revene of the quarter and ST30. million for helenty pear bayolution, dospital, dospital, dospital, dospital, t market sentiment, but balanced against financial and operational risks." Since the February recommendation, Axsome's stock has remained relatively unchanged. VAL 84.09 A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-4241907 (State or other ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Conference Call Participants Vikram Purohit - Morgan Stanley Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald Joon Lee - Truist Securities Raghuram Selvaraju - H.C. Wainwright Jason Gerberry - Bank of Ameri ...

Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth NDA for AXS-07 in migraine resubmitted Topline results of ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation an ...

Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth NDA for AXS-07 in migraine resubmitted Topline results of ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation anticipated 2H 2024 Topline results of ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 in Alzheimer's ...